Please assess the completion status of the following clinical trial:

Trial Title: Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with a diagnosis of idiopathic PD according to United Kingdom Parkinson's Disease Brain Bank Criteria~* mMIDI ≥ 3 score with ICD~* Patients must be on an anti-parkinson treatment at least 6 months before screening.~* for this protocol, dopamine agonists should be included in his/her anti-parkinson treatment.~* 30years ≤ patients \< 80years of age, male or female~* patients must give written informed consent before any assessment is performed~Exclusion Criteria:~* Requirement of treatment with serious cognitive disorder, behavioral disorder, or mental illness currently or in the future~* for the patients ≤ 65years: K-MMSE(korean version of Mini-Mental State Exam) ≤24, or for the patients ≥ 66years: K-MMSE ≤ 20, or the patients have dementia(incl. early dementia) even though K-MMSE score is more than 20~* Requirement of treatment more than 6times per day due to the severe motor fluctuation.~* Severe dyskinesia~* DBS(Deep Brain Stimulation)or any other surgical treatment~* History of melanoma or not-diagnostic skin trouble/skin lesions~* narrow angle glaucoma~* clinically serious surgical or medical condition~* malignant tumor~* use of other investigational drugs at the time of enrollment within 4weeks~* pregnant, nursing or lactating women~* women of child-bearing potential~* history of hypersensitivity or allergy to levodopa/carbidopa~* any serious disease according to the investigator's discretion

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Levodopa/Carbidopa(200mg/50mg) (Type: EXPERIMENTAL): None
- Control A (dopaminergic agonist ) (Type: EXPERIMENTAL): Parkinson patients treated with anti-Parkinson drug over 6 months.
- Control B (no drug) (Type: NO_INTERVENTION): Parkinson diseased patients not treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).